These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18162944)

  • 21. Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine.
    Palmu A; Jokinen J; Kilpi T;
    Vaccine; 2008 May; 26(20):2466-70. PubMed ID: 18420315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
    Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
    Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ; Fletcher MA; Fritzell B; Ciuryla V; Schranz J
    Vaccine; 2007 Mar; 25(13):2420-7. PubMed ID: 17049677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults.
    Benin AL; O'Brien KL; Watt JP; Reid R; Zell ER; Katz S; Donaldson C; Parkinson A; Schuchat A; Santosham M; Whitney CG
    J Infect Dis; 2003 Jul; 188(1):81-9. PubMed ID: 12825175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of the heptavalent pneumococcal vaccine against meningitis, pneumonia and acute otitis media in pediatric age. Theoretical coverage offered by the heptavalent conjugate vaccine in Italy].
    Principi N; Esposito S
    Ann Ig; 2002; 14(6 Suppl 7):21-30. PubMed ID: 12638361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children.
    Henckaerts I; Durant N; De Grave D; Schuerman L; Poolman J
    Vaccine; 2007 Mar; 25(13):2518-27. PubMed ID: 17034907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of pneumococcal conjugate vaccines on otitis media-can we extrapolate to pneumonia?
    Dagan R
    Vaccine; 2008 Jun; 26 Suppl 2():B16-8. PubMed ID: 18793601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Authors' reply to Prymula R. Re: "Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines" [Vaccine 27 (2009) 4739-4740].
    Rodgers GL; Arguedas A; Cohen R; Dagan R
    Vaccine; 2009 Sep; 27(40):5429-30. PubMed ID: 19643215
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
    Oosterhuis-Kafeja F; Beutels P; Van Damme P
    Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines.
    Prymula R
    Vaccine; 2009 Jul; 27(35):4739-40. PubMed ID: 19540951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of otitis media: now a reality?
    Schuerman L; Borys D; Hoet B; Forsgren A; Prymula R
    Vaccine; 2009 Sep; 27(42):5748-54. PubMed ID: 19666154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial.
    Brouwer CN; Maillé AR; Rovers MM; Veenhoven RH; Grobbee DE; Sanders EA; Schilder AG
    Pediatrics; 2005 Feb; 115(2):273-9. PubMed ID: 15687432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants.
    Eick A; Croll J; Weatherholtz R; Croll L; Santosham M
    Vaccine; 2004 Mar; 22(9-10):1260-4. PubMed ID: 15003655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect?
    Moore MR; Whitney CG
    Clin Infect Dis; 2008 Jan; 46(2):183-5. PubMed ID: 18171248
    [No Abstract]   [Full Text] [Related]  

  • 38. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of carriage and transmission of Streptococcus pneumoniae: the beneficial "side effect" of pneumococcal conjugate vaccine.
    Azzari C; Resti M
    Clin Infect Dis; 2008 Oct; 47(8):997-9. PubMed ID: 18781870
    [No Abstract]   [Full Text] [Related]  

  • 40. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species.
    Pletz MW; Maus U; Krug N; Welte T; Lode H
    Int J Antimicrob Agents; 2008 Sep; 32(3):199-206. PubMed ID: 18378430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.